Edward Mathers Purchases 207,100 Shares of Korro Bio (NASDAQ:KRRO) Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Edward Mathers bought 207,100 shares of the stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Performance

Shares of NASDAQ:KRRO opened at $12.80 on Friday. The company’s 50-day moving average is $10.99 and its 200 day moving average is $20.18. The company has a market capitalization of $120.58 million, a P/E ratio of -1.03 and a beta of 2.98. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89.

Korro Bio (NASDAQ:KRRO) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing the consensus estimate of ($1.93) by ($3.39). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 99.63%. The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. As a group, research analysts predict that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

Key Stories Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target, providing a prominent analyst endorsement that can attract momentum and institutional buyers. Read More.
• Positive Sentiment: Multiple major shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed large purchases (~207,100 shares at ~$11.11 each), signaling strong insider/large‑holder conviction and providing buying support. Read More.
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for hyperammonemia, is advancing a GalNAc oligo candidate for AAT deficiency (on track to nominate in Q2 2026), and closed an oversubscribed $85M private placement, which management says extends cash runway into H2 2028 — materially reducing near‑term financing risk. Read More.
• Neutral Sentiment: Revenue for Q4 modestly exceeded expectations ($1.29M vs. ~ $0.42M est.), but the amount is very small relative to R&D and operating burn, so near‑term profit improvement is limited. Read More.
• Negative Sentiment: Quarterly and annual results show heavy write‑downs and operating losses: Q4 EPS was a ($5.32) miss vs. consensus (~($1.93)), and full‑year net loss widened (reported ~$117.3M) driven by non‑cash impairment charges — highlighting high execution risk and potential for volatility if clinical progress stalls. Read More. Read More.

Hedge Funds Weigh In On Korro Bio

Several large investors have recently modified their holdings of the business. XTX Topco Ltd raised its position in shares of Korro Bio by 31.1% in the fourth quarter. XTX Topco Ltd now owns 57,067 shares of the company’s stock valued at $457,000 after purchasing an additional 13,529 shares during the period. Quadrature Capital Ltd bought a new position in Korro Bio in the 4th quarter worth approximately $217,000. Engineers Gate Manager LP purchased a new position in Korro Bio in the 4th quarter valued at approximately $215,000. Guggenheim Capital LLC purchased a new position in Korro Bio in the 4th quarter valued at approximately $84,000. Finally, Jain Global LLC bought a new stake in Korro Bio during the 4th quarter valued at $85,000. Hedge funds and other institutional investors own 13.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KRRO. Raymond James Financial upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research note on Friday. JonesTrading downgraded Korro Bio from a “buy” rating to a “hold” rating in a research note on Friday, November 14th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. Finally, Cantor Fitzgerald boosted their target price on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.